Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 3 N=362 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 52.3 percentage of subjects — p=<0.0001
Merz North America, Inc. Results May 2024 0.8% serious AE View details

Phase 3 N=368 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 49.5 percentage of subjects — p=<0.0001
Merz North America, Inc. Results Aug 2024 2.5% serious AE View details

Phase 4 N=250 The Treatment of Glabellar Frown Lines

Glabellar Frown Lines
Primary: Efficacy, Measured as the Percentage of Participants Who Responded to Treatment — 95.7; 99.2 percentage of participants
Merz North America, Inc. Results Mar 2017 0.8% serious AE View details

Phase 3 N=101 BOTOX® in the Treatment of Upper Facial Lines in Japan

Upper Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle…
Allergan Results Feb 2015 5.0% serious AE View details

Phase 3 N=234 MT10109L in the Treatment of Glabellar Lines

Glabellar Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND…
Medy-Tox Results Jun 2023 2.6% serious AE View details

Phase 2 N=48 ET-01 in Subjects With Lateral Canthal Lines

Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2 — 2; 3; 4; 2…
Eirion Therapeutics Inc. Results Sep 2021 0.0% serious AE View details

Phase 2 N=75 ET-01 in Subjects With Lateral Canthal Lines, LCL-208

Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 2; 0; 1…
Eirion Therapeutics Inc. Results Jul 2022 0.0% serious AE View details

Phase 2 N=79 ET-01 in Subjects With Lateral Canthal Lines, LCL-207

Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 4; 1; 3…
Eirion Therapeutics Inc. Results Feb 2022 3.8% serious AE View details

Phase 2 N=38 ET-01 in Subjects With Lateral Canthal Lines, LCL-209

Lateral Canthal Lines, LCL · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 3; 1…
Eirion Therapeutics Inc. Results Jun 2022 0.0% serious AE View details